Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The provided evaluation content is largely correct only for the boxed warning/neuraxial hematoma claim, but the overall included claims about Lovenox formulation/excipients are not supported by the supplied prescribing-information excerpts, which focus on spinal/epidural hematomas rather than inactive-ingredient composition.
Category Scores
Accurate Statements
Epidural or spinal hematomas may occur in patients anticoagulated with enoxaparin sodium (Lovenox) who are receiving neuraxial anesthesia or undergoing spinal puncture, and may result in long-term or permanent paralysis; risk is increased by factors such as indwelling epidural catheters and concomitant drugs affecting hemostasis (e.g., NSAIDs/anticoagulants).
Supported by BOXED WARNING (WARNING: SPINAL/EPIDURAL HEMATOMAS) and Section 5.1 (Increased Risk of Hemorrhage), including occurrence/outcome and listed risk factors.
Unsupported Statements
Lovenox (enoxaparin) is formulated as an injection.
The supplied label excerpts do not include formulation/ dosage form or inactive-ingredient composition details.
Lovenox uses inactive ingredients/excipients to help stabilize the drug and make it deliverable as a solution.
No inactive-ingredient/excipient description is present in the supplied excerpts.
The exact inactive-ingredient list for Lovenox can vary by package type.
Inactive-ingredient variability by package type is not described in the supplied excerpts.
The exact inactive-ingredient list for Lovenox can vary by country/label.
No country/label-dependent inactive-ingredient discussion is present in the supplied excerpts.
Inactive ingredients can differ between Lovenox presentations (vial vs. syringe).
No formulation presentation/inactive-ingredient comparison is present in the supplied excerpts.
Inactive ingredients can differ between Lovenox strengths.
No strength-dependent inactive-ingredient statement is present in the supplied excerpts.
Even when the active ingredient is the same (enoxaparin), the excipient list can differ by presentation and label version.
No inactive-ingredient list or version/presentation variability is provided in the supplied excerpts.
For allergy/reaction checks, the excipient list should come from the specific product label the patient is using.
The supplied label excerpts do not discuss excipient review for allergy/reaction purposes.
The most reliable source for the inactive-ingredient list is the specific prescribing information or package insert for the exact Lovenox presentation.
The supplied excerpts do not discuss where to source inactive-ingredient lists.
Contradictions
Important Omissions
No dosing/administration details, timing for neuraxial catheter placement/removal, monitoring instructions, or contraindications are provided for evaluation within the supplied AI claims (the excerpted label text includes specific timing and monitoring, but none of that was claimed).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-relevant boxed-warning content about spinal/epidural hematomas is supported, but multiple claims about excipients/inactive ingredients are unsupported by the provided labeling excerpts, which could mislead readers about composition or allergy-check procedures.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Inactive-ingredient/excipient claims are not supported by the supplied FDA label excerpts; only neuraxial hematoma risk statements are supported.
Suggested Improvement
Limit claims to label-supported safety information in the provided excerpts (e.g., boxed warning and Section 5.1) and remove or separately substantiate inactive-ingredient/presentation/country variability claims using the specific inactive-ingredient sections of the prescribing information for the exact product.